In one study, the UK-based firm found that its RaDaR assay detected circulating tumor DNA in lung cancer patients up to a year before standard clinical progression occurred in most of the cases.
Polygenic risk scores have the potential to impact cancer screening, autoimmune disease testing, and therapeutics development, but more diverse data is needed.
With studies showing BRCA-mutated patients have a greater magnitude of benefit, oncologists grapple with complex treatment decisions in BRCA mutation-free cases.
The agency based its decision on the results of the POLO trial, in which patients on olaparib had a median progression-free survival of 7.4 months compared to 3.8 months on placebo.
The agency made its decision based on the SOLAR-1 study showing a five-month progression-free survival benefit for Piqray plus fulvestrant over just fulvestrant.
